» Articles » PMID: 23222683

Antiviral Activity of Baicalein and Quercetin Against the Japanese Encephalitis Virus

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2012 Dec 11
PMID 23222683
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Japanese encephalitis (JE), a mosquito-borne viral disease, is endemic to the entire east and southeast Asia, and some other parts of the world. Currently, there is no effective therapeutic available for JE; therefore, finding the effective antiviral agent against JEV replication is crucial. In the present study, the in vitro antiviral activity of baicalein and quercetin, two purportedly antiviral bioflavonoids, was evaluated against Japanese encephalitis virus (JEV) replication in Vero cells. Anti-JEV activities of these compounds were examined on different stages of JEV replication cycle. The effects of the compounds on virus replication were determined by foci forming unit reduction assay (FFURA) and quantitative RT-PCR. Baicalein showed potent antiviral activity with IC(50) = 14.28 µg/mL when it was introduced to the Vero cells after adsorption of JEV. Quercetin exhibited weak anti-JEV effects with IC(50) = 212.1 µg/mL when the JEV infected cells were treated with the compound after virus adsorption. However, baicalein exhibited significant effect against JEV adsorption with IC(50) = 7.27 µg/mL while quercetin did not show any anti-adsorption activity. Baicalein also exhibited direct extracellular virucidal activity on JEV with IC(50) = 3.44 µg/mL. However, results of quantitative RT-PCR experiments confirmed the findings from FFURA. This study demonstrated that baicalein should be considered as an appropriate candidate for further investigations, such as the study of molecular and cellular mechanism(s) of action and in vivo evaluation for the development of an effective antiviral compound against Japanese encephalitis virus.

Citing Articles

NS2B-D55E and NS2B-E65D Variations Are Responsible for Differences in NS2B-NS3 Protease Activities Between Japanese Encephalitis Virus Genotype I and III in Fluorogenic Peptide Model.

Wahaab A, Zhang Y, Liu K, Rasgon J, Kang L, Hameed M Int J Mol Sci. 2024; 25(23).

PMID: 39684391 PMC: 11641239. DOI: 10.3390/ijms252312680.


Identification and characterization of HP-B1083-derived β-glucuronidase and its application for baicalin biotransformation.

Ji X, Xiao Y, Sun R, Tan Z, Zhu Y, Li X Heliyon. 2024; 10(18):e38028.

PMID: 39323839 PMC: 11422588. DOI: 10.1016/j.heliyon.2024.e38028.


Natural products and derivatives as Japanese encephalitis virus antivirals.

Mi Y, Guo Y, Luo X, Bai Y, Chen H, Wang M Pathog Dis. 2024; 82.

PMID: 39317665 PMC: 11556344. DOI: 10.1093/femspd/ftae022.


Evaluation of three alternative methods to the plaque reduction neutralizing assay for measuring neutralizing antibodies to dengue virus serotype 2.

Goh V, Ang C, Low S, Lee P, Setoh Y, Wong J Virol J. 2024; 21(1):208.

PMID: 39227969 PMC: 11373480. DOI: 10.1186/s12985-024-02459-y.


Development of Fusion-Based Assay as a Drug Screening Platform for Nipah Virus Utilizing Baculovirus Expression Vector System.

Sari I, Ortiz C, Yang L, Chen M, Perng M, Wu T Int J Mol Sci. 2024; 25(16).

PMID: 39201788 PMC: 11354753. DOI: 10.3390/ijms25169102.


References
1.
Shabrova E, Tarnopolsky O, Singh A, Plutzky J, Vorsa N, Quadro L . Insights into the molecular mechanisms of the anti-atherogenic actions of flavonoids in normal and obese mice. PLoS One. 2011; 6(10):e24634. PMC: 3189911. DOI: 10.1371/journal.pone.0024634. View

2.
Santhosh S, Parida M, Dash P, Pateriya A, Pattnaik B, Pradhan H . Development and evaluation of SYBR Green I-based one-step real-time RT-PCR assay for detection and quantification of Chikungunya virus. J Clin Virol. 2007; 39(3):188-93. DOI: 10.1016/j.jcv.2007.04.015. View

3.
Hsiao N, Chen J, Yang T, Orloff G, Wu Y, Lai C . ISG15 over-expression inhibits replication of the Japanese encephalitis virus in human medulloblastoma cells. Antiviral Res. 2009; 85(3):504-11. DOI: 10.1016/j.antiviral.2009.12.007. View

4.
Gubler D . Emerging vector-borne flavivirus diseases: are vaccines the solution?. Expert Rev Vaccines. 2011; 10(5):563-5. DOI: 10.1586/erv.11.35. View

5.
Gould E, Solomon T, MacKenzie J . Does antiviral therapy have a role in the control of Japanese encephalitis?. Antiviral Res. 2007; 78(1):140-9. DOI: 10.1016/j.antiviral.2007.10.005. View